NEW

Activ Surgical Announces FDA Clearance for ActivSight Intraoperative Imaging Module

Activ Surgical announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ActivSight Intraoperative Imaging Module for enhanced surgical visualization.

Metrex Surface Disinfectant Portfolio Secures EPA Approval

The U.S. Environmental Protection Agency (EPA) has approved all eight surface disinfectant products made by an infection prevention leader, Metrex, as effective against SARS-CoV-2, the novel coronavirus that causes COVID-19.

Olympus Supports Safety Actions Regarding Surgical Smoke

Olympus has announced its support of The Joint Commission’s recommended safety actions for managing the hazards of exposure to surgical smoke for health care staff in operating rooms.

Exofin Fusion Redesign Receives FDA Approval

Chemence Medical, a leader in medical cyanoacrylate devices and products, announced the U.S. Federal Drug Administration’s (FDA) 510(k) approval of the company’s redesigned exofin fusion skin closure system.

Ultrapotent compound may help treat C. diff, reduce recurrence

Herman O. Sintim, the Drug Discovery Professor of Chemistry in Purdue’s Department of Chemistry, has helped advance novel compounds to help treat patients with C. diff.

Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S.

Only two antibiotics, vancomycin and fidaxomicin, are FDA-approved for the treatment of C. diff, but even these therapies suffer from high treatment failure and recurrence.

Now, Purdue University innovators have advanced novel compounds that they developed to help treat patients with C. diff, one of only four bacteria considered an urgent threat by the Centers for Disease Control and Prevention. Their work is published in the Journal of Medicinal Chemistry.

“Our compounds have several advantages, including ultrapotent activities with minimum inhibitory concentration values as low as 0.003 μg/mL,” said Herman O. Sintim, the Drug Discovery Professor of Chemistry in Purdue’s Department of Chemistry. “Our compounds also do not kill good bacteria at concentrations that kill C. diff and performed significantly better than current antibiotics in preventing recurrence. These are significant advantages for patients dealing with this difficult bacterial infection.”

The most promising of the Purdue compounds, containing trifluoromethylthio functional group, is HSGN-218. Sintim said it has been shown to be one of the most potent compounds ever produced for use against C. diff.

“This is part of our work to create new solutions to treat diseases and infections that are resistant to current treatment options,” said Sintim, who is a member of the Purdue University Center for Cancer Research and the Purdue Institute for Drug Discovery. “This work provides a potential clinical lead for the development of C. diff therapeutics and also highlights dramatic drug potency enhancement via halogen substitution.”

The researchers patented their compounds through the Purdue Research Foundation Office of Technology Commercialization, which is looking for partners to advance the technology. For more information, contact Joseph Kasper at OTC at jrkasper@prf.org and mention track code 2019-SINT-68535.

George Naclerio, a researcher on Sintim’s team, has been awarded a National Institutes of Health T32 training grant to help facilitate the development of this technology.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X